Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer

Targeting the KRAS pathway is a promising but challenging approach for colorectal cancer therapy. Despite showing potent efficacy in BRAF-mutated melanoma, MEK inhibitors appeared to be tolerated by colorectal cancer cells due to their intrinsic compensatory signaling. Here, we performed genome-wide...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Chune, Luo, Dan, Yu, Jing, Zhang, Min, Zheng, Xiaobo, Xu, Guangchao, Wang, Jiaxin, Wang, Huiling, Xu, Yufei, Jiang, Ke, Xu, Jie, Ma, Xuelei, Jing, Jing, Shi, Hubing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732282/
https://www.ncbi.nlm.nih.gov/pubmed/34718347
http://dx.doi.org/10.1038/s41388-021-02077-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732282/
https://www.ncbi.nlm.nih.gov/pubmed/34718347
http://dx.doi.org/10.1038/s41388-021-02077-w

Ejemplares similares